Opinion

Video

The CSF-1R Signaling Pathway in GVHD and Investigational Agents Targeting this Pathway

Author(s):

Hannah Choe, MD

Dr. Choe discusses the potential role of the CSF-1R signaling pathway in the pathogenesis of numerous diseases, including GVHD. A video segment explores how dysregulation of this pathway can contribute to the development and progression of GVHD, providing the rationale for targeting CSF-1R as a potential therapeutic strategy.

Related Videos
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Related Content
Justin M. Watts, MD
July 22nd 2024

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Brentuximab Vedotin Triplet in R/R DLBCL Subgroups | Image Credit: © freshidea - stock.adobe.com
July 17th 2024

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Francisco Hernandez-Ilizaliturri, MD, of Roswell Park
July 17th 2024

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.
July 16th 2024

FDA Places Partial Clinical Hold on Phase 1 Trial of Seclidemstat Plus Azacitidine in MDS/CMML